生益電子(688183.SH):截止目前尚未向英偉達供貨
格隆匯5月30日丨有投資者向生益電子(688183.SH)提問,“公司提到800G的光模塊已經小批量供貨,是否向英偉達供貨。如何做大做強光模塊業務。”
生益電子回覆稱,公司自成立以來始終專注於PCB的研發、生產與銷售業務,且長期深耕高速PCB領域,有多年的光模塊PCB製造經驗,加工技術得到多家行業知名客户認可。截止目前,公司尚未向英偉達供貨。隨着公司東城工廠(四期)5G應用領域高速高密印製電路板擴建升級項目的投產,將進一步豐富公司的產品線,增加HDI產品的產能和HDI產品的技術能力,進一步強化公司的綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.